Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
103 Results for "
CD85
" in MedChemExpress (MCE) Product Catalog:
Products (103)
103 Results for "CD85" in MCE Product Catalog:
Cat. No.: HY-P990092
CAS No.: 2723442-10-0
Target:
Research Areas:
Cat. No.: HY-P990462
Target:
Research Areas:
Cat. No.: HY-P991307
Target:
Research Areas:
Cat. No.: HY-P78900
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: LILRB1; CD85 Antigen-Like Family Member J; Leukocyte Immunoglobulin Like Receptor B1; Myeloid Inhibitory Receptor 7; LIR-1; Leucocyte Ig-Like Receptor B1; MIR-7; ILT-2; ILT2; CD85; LIR1; MIR7; CD85j; Immunoglobulin Heavy Chain Variable Region; PIR-B; Leuk
Species:
Human
Source:
HEK293
Cat. No.: HY-P991308
Target:
Cat. No.: HY-RS07649
Target:
Research Areas:
LILRA5 Human Pre-designed siRNA Set A contains three designed siRNAs for LILRA5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-P70179
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: LILRB1; CD85 Antigen-Like Family Member J; Leukocyte Immunoglobulin Like Receptor B1; Myeloid Inhibitory Receptor 7; LIR-1; Leucocyte Ig-Like Receptor B1; MIR-7; ILT-2; ILT2; CD85; LIR1; MIR7; CD85j; Immunoglobulin Heavy Chain Variable Region; PIR-B; Leuk
Species:
Human
Source:
HEK293
Cat. No.: HY-P70182
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: LILRB1; CD85 Antigen-Like Family Member J; Leukocyte Immunoglobulin Like Receptor B1; Myeloid Inhibitory Receptor 7; LIR-1; Leucocyte Ig-Like Receptor B1; MIR-7; ILT-2; ILT2; CD85; LIR1; MIR7; CD85j; Immunoglobulin Heavy Chain Variable Region; PIR-B; Leuk
Species:
Human
Source:
HEK293
Cat. No.: HY-P72520
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: LILRB1; CD85 Antigen-Like Family Member J; Leukocyte Immunoglobulin Like Receptor B1; Myeloid Inhibitory Receptor 7; LIR-1; Leucocyte Ig-Like Receptor B1; MIR-7; ILT-2; ILT2; CD85; LIR1; MIR7; CD85j; Immunoglobulin Heavy Chain Variable Region; PIR-B; Leuk
Species:
Rhesus Macaque
Source:
HEK293
Cat. No.: HY-P77980
Purity: ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: LILRB1; CD85 Antigen-Like Family Member J; Leukocyte Immunoglobulin Like Receptor B1; Myeloid Inhibitory Receptor 7; LIR-1; Leucocyte Ig-Like Receptor B1; MIR-7; ILT-2; ILT2; CD85; LIR1; MIR7; CD85j; Immunoglobulin Heavy Chain Variable Region; PIR-B; Leuk
Species:
Human
Source:
HEK293
Cat. No.: HY-P77982
Purity: ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: LILRB1; CD85 Antigen-Like Family Member J; Leukocyte Immunoglobulin Like Receptor B1; Myeloid Inhibitory Receptor 7; LIR-1; Leucocyte Ig-Like Receptor B1; MIR-7; ILT-2; ILT2; CD85; LIR1; MIR7; CD85j; Immunoglobulin Heavy Chain Variable Region; PIR-B; Leuk
Species:
Human
Source:
HEK293
Cat. No.: HY-P72395
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: LILRB1; CD85 Antigen-Like Family Member J; Leukocyte Immunoglobulin Like Receptor B1; Myeloid Inhibitory Receptor 7; LIR-1; Leucocyte Ig-Like Receptor B1; MIR-7; ILT-2; ILT2; CD85; LIR1; MIR7; CD85j; Immunoglobulin Heavy Chain Variable Region; PIR-B; Leuk
Species:
Human
Source:
HEK293
Cat. No.: HY-P77981
Purity: ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: LILRB1; CD85 Antigen-Like Family Member J; Leukocyte Immunoglobulin Like Receptor B1; Myeloid Inhibitory Receptor 7; LIR-1; Leucocyte Ig-Like Receptor B1; MIR-7; ILT-2; ILT2; CD85; LIR1; MIR7; CD85j; Immunoglobulin Heavy Chain Variable Region; PIR-B; Leuk
Species:
Human
Source:
HEK293
Cat. No.: HY-P77985
Purity: ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: LILRB1; CD85 Antigen-Like Family Member J; Leukocyte Immunoglobulin Like Receptor B1; Myeloid Inhibitory Receptor 7; LIR-1; Leucocyte Ig-Like Receptor B1; MIR-7; ILT-2; ILT2; CD85; LIR1; MIR7; CD85j; Immunoglobulin Heavy Chain Variable Region; PIR-B; Leuk
Species:
Human
Source:
HEK293
Cat. No.: HY-P78325
Purity: ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: LILRB1; CD85 Antigen-Like Family Member J; Leukocyte Immunoglobulin Like Receptor B1; Myeloid Inhibitory Receptor 7; LIR-1; Leucocyte Ig-Like Receptor B1; MIR-7; ILT-2; ILT2; CD85; LIR1; MIR7; CD85j; Immunoglobulin Heavy Chain Variable Region; PIR-B; Leuk
Species:
Rhesus Macaque
Source:
HEK293
Cat. No.: HY-P701017
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: LILRB1; CD85 Antigen-Like Family Member J; Leukocyte Immunoglobulin Like Receptor B1; Myeloid Inhibitory Receptor 7; LIR-1; Leucocyte Ig-Like Receptor B1; MIR-7; ILT-2; ILT2; CD85; LIR1; MIR7; CD85j; Immunoglobulin Heavy Chain Variable Region; PIR-B; Leuk
Species:
Cynomolgus
Source:
HEK293
Cat. No.: HY-P77740
Purity: ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: LILRB1; CD85 Antigen-Like Family Member J; Leukocyte Immunoglobulin Like Receptor B1; Myeloid Inhibitory Receptor 7; LIR-1; Leucocyte Ig-Like Receptor B1; MIR-7; ILT-2; ILT2; CD85; LIR1; MIR7; CD85j; Immunoglobulin Heavy Chain Variable Region; PIR-B; Leuk
Species:
Rhesus Macaque
Source:
HEK293
Cat. No.: HY-P700778
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: LILRB1; CD85 Antigen-Like Family Member J; Leukocyte Immunoglobulin Like Receptor B1; Myeloid Inhibitory Receptor 7; LIR-1; Leucocyte Ig-Like Receptor B1; MIR-7; ILT-2; ILT2; CD85; LIR1; MIR7; CD85j; Immunoglobulin Heavy Chain Variable Region; PIR-B; Leuk
Species:
Rhesus Macaque
Source:
HEK293
Cat. No.: HY-P992215
Target:
Research Areas:
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
